The latest price in 2024: Avatrombopag’s listing price report!

Avatrombopag is an oral medication that is a thrombopoietin receptor agonist. Its main function is to increase the number of platelets by stimulating platelet production in the bone marrow, thereby preventing or treating diseases related to thrombocytopenia, especially immune thrombocytopenic purpura (ITP).

Avatrombopag is now on the market in China and has been successfully included in the medical insurance system. Patients can purchase it directly in China, and the price is roughly in the range of three to four thousand yuan. For specific pricing information and medical insurance reimbursement details, please consult your local hospital pharmacy directly for accurate information. It is worth mentioning that the price of foreign generic drugs of avatrombopag is more affordable, especially the generic drugs listed in Laos and Bangladesh, which are only priced at a few hundred to one thousand yuan. The ingredients of these generic drugs are basically the same as those of the original drugs.

Immune thrombocytopenic purpura is an autoimmune disease in which a patient's immune system mistakenly attacks their own platelets, resulting in a reduced number of platelets and an increased risk of bleeding. Avatrombopag stimulates platelet production in the bone marrow by simulating the effect of thrombopoietin, thereby increasing the number of platelets, helping to maintain normal coagulation function and reducing the occurrence of bleeding events.

In addition, avatrombopag is used to treat thrombocytopenia caused by liver problems in patients with chronic liver disease, such as chronic hepatic thrombocytopenic purpura (HCVrelated cirrhosis).

Although avatrombopag has shown good efficacy in increasing platelet count, there are also some possible side effects during use, such as headache, nausea, fatigue, etc. Therefore, patients should pay close attention to any adverse reactions when using this drug and report it to their doctor in a timely manner. The determination of whether to use avatrombopag and the selection of dosage should be evaluated and guided by a physician based on the patient's specific situation.